The present review shows a listing of medicinal plants used in phytotherapy of diabetes and those experimentally studied as hypoglycaemic in Morocco. The review is presented as 3 tables. The first one includes the taxonomic classification of the plant, the popular names in Morocco, the parts used, the mode of preparation and the other medicinal uses and toxicity. The second table summarises the experiments done by Moroccan researchers to confirm the hypoglycemic activity of the medicinal plants. It also describes the methodology used, and the magnitude of the hypoglycemic activity. The third table lists the toxicological studies carried out with plants reported to be toxic. The large number of plants described in this review (94 species belonging to 38 families) demonstrated the prevalence of phytotherapy in Morocco. The plant families which contained the most commonly used species for their antidiabetic effects are: Compositae (18 species), Lamiaceae (14 sp.), Leguminosae (8 sp.), Liliaceae (5 sp.), Apiaceae (5 sp.), and Graminae (4 sp.). Among these medicinal plants, 17 are toxic, the most known being: Daphne gnidium, Nerium oleander, Ferula communis, Peganum harmala and Citrullus colocynthis.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.